In conclusion, a profound knowledge of the clinical phenotypes associated with different pathogenic variants of SOD1-ALS will be important in the future in order to accelerate diagnosis and ensure early initiation of tofersen therapy. Here, SOD1 is linked to amyotrophic lateral sclerosis.